Grand Pharmaceutical's TP-03 Ophthalmic Solution Reaches First Commercial Prescriptions at 11 Mainland China Hospitals

Grand Pharmaceutical Group (0512.HK) has delivered the first commercial prescriptions of its ophthalmic product Manmu'an (TP-03, lotilaner ophthalmic solution 0.25%) in mainland China, at 11 medical institutions across Beijing, Shanghai, Guangdong, Tianjin, Chongqing, Zhejiang, Fujian, Hubei and Shaanxi, for demodex blepharitis. The source calls it the first and only approved product for this indication in Greater China, and reports US sales of about $450 million in 2025 and about $320 million in the first half of 2026.